KRAS and familial pancreatic carcinoma: Wang et al. have recently utilized a positive selection screen on two KRAS-mutant pancreatic cancer cell lines to identify factors that confer survival and proliferation to trametinib, a drug that inactivates the MAPK pathway through inactivation of MEK [47].